jte 522 has been researched along with Bladder Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kamoi, K; Kawauchi, A; Miki, T; Mizutani, Y; Ukimura, O | 1 |
| Kawauchi, A; Li, YN; Miki, T; Mizutani, Y; Nakanishi, H; Sato, N | 1 |
2 other study(ies) available for jte 522 and Bladder Cancer
| Article | Year |
|---|---|
Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Benzenesulfonates; Blotting, Western; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Synergism; Fluorouracil; Humans; Isoenzymes; Male; Membrane Proteins; Oxazoles; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2002 |
Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Transitional Cell; Cell Division; Cell Line, Tumor; Cell Survival; Cisplatin; Cyclooxygenase Inhibitors; Drug Synergism; Female; Humans; Mice; Mice, SCID; Neoplasm Transplantation; Oxazoles; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Stem Cell Assay; Urinary Bladder Neoplasms | 2004 |